In Brief: Sonus Pharmaceuticals' EchoGen
Sonus Pharmaceuticals' EchoGen: NDA submitted Aug. 12 for perflenapent emulsion, a fluorocarbon-based ultrasound contrast agent. Filing triggers $4 mil. milestone payment from U.S. marketer Abbott Labs. Sonus also recently earned a $3 mil. milestone payment from Daiichi, which will market and distribute product in Pacific Rim. According to Bothell, Wash.-based Sonus, EchoGen has a diagnostic sensitivity of 89%, specificity of 97%, a positive predictive value of 98%, negative predictive value of 84% and an overall accuracy of 92%...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth